Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799163 | 0.74 | TSHR (0.41) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL15845026 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9APKMALDH1A1 | |
| SCHEMBL1090093 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9APKMALDH1A1 | |
| SCHEMBL1802768 | 0.72 | HTT (0.41) | SMN1; SMN2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL31461530 | 0.72 | CA12 (0.39) | SMN1; SMN2PKMALDH1A1MEN1KMT2A | |
| SCHEMBL26042973 | 0.70 | KDM4E (0.53) | SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL30394130 | 0.70 | GAA (0.49) | SMN1; SMN2KDM4EALDH1A1CA12CA1 | |
| SCHEMBL26451646 | 0.70 | KDM4E (0.53) | SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL2129974 | 0.69 | AAK1 (0.42) | SMN1; SMN2RAB9APKMKDM4EALDH1A1 | |
| SCHEMBL2715770 | 0.69 | AAK1 (0.42) | SMN1; SMN2RAB9APKMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951972-B2 | Human adam-10 inhibitors | EXELIXIS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | disclosed |
| US-7498358-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | EXELIXIS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20050227973-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227973-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, ADAM9 | SMN1; SMN2 4037/4885NPC1 2401/4885RAB9A 2137/4885 |
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | SMN1; SMN2 4368/4885NPC1 1986/4885RAB9A 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.